Platelet aggregation phenotypic system

Platelet aggregation phenotypic system refers to a functional biological assay used to identify compounds that inhibit the clumping of platelets, a process central to both physiological hemostasis and pathological thrombosis (StatPearls, 2023). This classification is typically used in pharmacological databases, such as ChEMBL, when a compound demonstrates a clear anti-aggregatory effect in whole blood or platelet-rich plasma, but the specific molecular receptor or enzyme it binds to remains unidentified (Nature Reviews Drug Discovery, 2011). Platelets are small, disc-shaped cell fragments that, upon activation by stimuli like collagen or ADP, undergo shape changes and express surface receptors that allow them to cross-link via fibrinogen (PubMed, PMID: 30234145). While this process is vital for stopping blood loss, overactive aggregation can lead to the formation of occlusive thrombi in arteries, causing heart attacks and strokes (American Heart Association, 2024). Therapeutic agents that modulate this system are cornerstone treatments in cardiology, though they must balance efficacy in preventing clots with the risk of causing significant bleeding (NIH, 2023). Because this is a phenotypic target, it serves as a broad category for diverse chemical entities that may eventually be mapped to specific targets like P2Y12, COX-1, or Glycoprotein IIb/IIIa (PubChem, 2024).

Other names

Platelet aggregation - phenotypic system, precise molecular target unknownPlatelet aggregation assayPhenotypic antiplatelet activityUnspecified platelet target

Inhibition of platelet aggregation through various or unidentified molecular pathways.